PATENT
039363-1202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ibrahim et al.

Title: PYK2 CRYSTAL STRUCTURE AND USES

Appl. No.: 10/789,818

Filing Date: 02/27/2004

Examiner: Nashed

Art Unit: 1646

Conf. No. 5635

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: **Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450**, on the date below.

ANITA PATEL
(Printed Name)

(Signature)

NOVEMBER 10, 2006
(Date of Deposit)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313 1450

IDS TRANSMITTAL

Sir:

Transmitted herewith for the above-identified application please find:

(1) Information Disclosure Statement

(2) Completed Form PTO/SB/08

(3) Copies of the cited references A14-A60

(4) A credit card authorization form in the amount of $ 180.00
(5) Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 11/10/06

By _____
Richard J. Warburg
Attorney for Applicant
Registration No. 32,327

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6700
Facsimile: (858) 792-6773

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ibrahim et al.

Title: PYK2 CRYSTAL STRUCTURE AND USES

Appl. No.: 10/789,818

Filing Date: 02/27/2004

Examiner: Nashed, Nashaat T.

Art Unit: 1646

Confirmation Number: 5635

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**, on the date below.

ANITA PATEL
(Printed Name)

(Signature)

NOVEMBER 10 2006
(Date of Deposit)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment-IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of $180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of $180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit

card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 4/10/01

By _____

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6767
Facsimile: (858) 792-6773

Richard J. Warburg
Attorney for Applicant
Registration No. 32,327

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	10/789,818
Filing Date	02/27/2004
First Named Inventor	Prabha Ibrahim
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	039363-1202

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5698401		Fesik et al.	12-16-1997	
	A2	5804390		Fesik et al.	09-08-1998	
	A3	6197495		Qui et al.	03-06-2001	
	A4	6297021		Nienaber et al.	10-02-2001	
	A5	6465484		Bilodeau et al.	10-15-2002	
	A6	20020048782		Lev et al.	04-25-2002	
	A7	20010008765		Shinoki, Hiroshi et al.	07/19/2001	
	A8	20010012537		Anderson, Norman G. et al.	08/09/2001	
	A9	20010014448		Chappa, Ralph A. et al.	08/16/2001	
	A10	20010014449		Nerenberg, Michael et al.	08/16/2001	
	A11	20010016322		Caren, Michael P. et al.	08/23/2001	
	A12	20010018642		Balaban, David et al.	08/30/2001	
	A13	20010019827		Dawson, Elliott P. et al.	09/06/2001	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number	U.S. Patent Application Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A14	EP	0,154,734		Immunex Corporation	08-29-1990		
	A15	WO	96/18738		Sugen, Inc.	06-20-1996		
	A16	WO	97/46313		Array Technologies	12-11-1997		
	A17	WO	98/35056		Merck & Co., Inc.	08-13-1998		
	A18	WO	99/63931		The Salk Institute for Biological Studies	12-16-1999		
	A19	WO	99/09217		Hyseq, Inc.	02-25-1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	039363-1202

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A20	WO	99/26966		The Regents of the University of California	06-03-1999		
	A21	WO	99/51773		Phylos, Inc.	10-14-1999		
	A22	WO	01/58951		Stichting Voor de Technische Wetenschappen	08-16-2001		
	A23	WO	02/24722		Prochon Biotech Ltd.	03-28-2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A24	Ashani and Wilson, A covalent affinity column for the purification of acetylcholinesterase. Biochem. Biophys. Acta, 276:317-322, 1972.	
	A25	BOEHM, *et al.*, "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening," *J. Med. Chem.* 43:2664-2674 (2000)	
	A26	BOHACEK, *et al.*, "Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a *de Novo* Design Method Incorporating Combinatorial Growth," *J. Am. Chem. Soc.* 116:5560-5571 (1994)	
	A27	CHONG, *et al.*, "Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7," *PNAS* 96:14330-14335 (1999)	
	A28	COE and STORER, "Solution-phase combinatorial chemistry." Molecular Diversity, 4:1-38, 1999.	
	A29	CORNELL, *et al.*, "A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules," *J. Am. Chem. Soc.* 117:5179-5197 (1995)	
	A30	DONINI and KOLLMAN, "Calculation and Prediction of Binding Free Energies for the Matrix Metalloproteinases," *J. Med. Chem.* 43:4180-4188 (2000)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A31	DOWNS and WILLETT, "Similarity Searching and Clustering of Chemical-Structure Databases Using Molecular Property Data," *J. Chem. Inf. Comput. Sci.* 34:1094-1102 (1994)	
	A32	ELCOCK, Realistic modeling of the denatured states of proteins allows accurate calculations of the pH dependence of protein stability. Journal of Molecular Biology, 294:1051-1062, 1999.	
	A33	FEINBERG et al., Zinc-directed inhibitors for zinc proteinases. Acta Cryst., D51: 428-449, 1995.	
	A34	FELDER, E.R., "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development," *Chimia* 48:531-541 (1994)	
	A35	FITZGERALD et al., Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. The Journal of Biological Chemistry, 265 (24): 14209-14219, 1990.	
	A36	GELLER et al., HIV-1 protease and its inhibitors in Theoretical and Computational Mthods in Genome Research. Edited by Sahai. New York: Plenum Press, 1997, p. 237-254.	
	A37	HENDRICKSON and OGATA, "Phase Determination from Multiwavelength Anomalous Diffraction Measurements," *Methods of Enzymology* 276:494-523 (1997)	
	A38	HENDRICKSON *et al.*, "Selenomethionyl Proteins Produced for Analysis by Multiwavelength Anomalouse Diffraction (MAD): a Vehicle for Direct Determination of Three-Dimensional Structure," *The EMBO Journal* 9(5):1665-1672 (1990)	
	A39	JARVIS and PATRICK, "Clustering Using a Similarity Measure Based on Shared Near Neighbors," *IEEE Transactions on Computers* 11:1025-1034 (1973)	
	A40	KLEINBERG and WANKE, New approaches and technologies in drug design and discovery. Am. J. Health-Syst Pharm., 52: 1323-1336, 1995.	
	A41	LEBL *et al.*, "One-Bead-One-Structure," *Biopolymers (Peptide Science)* 37:177-198 (1995)	
	A42	MASSOVA and KOLLMAN, "Computational Alanine Scanning to Probe Protein – Protein Interactions: A Novel Approach to Evaluate Binding Free Energies," *Journ. of Amer. Chem. Soc.* 121(36):8133-8143 (1999)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A43	MCGOVERN, *et al.*, "A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening," *J. Med. Chem.* 45:1712-1722 (2002)	
	A44	MCPHERSON et al., The Role of X-ray crystallography in structure-based rational drug designs. Chapter 6 in Chemical Structures Approaches Ration. Drug Design. Edited by D.V. Weiner et al. Boca Raton: CRC Press, 1995, p. 161-179.	
	A45	NAGAR *et al.*, "Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecular Inhibitors PD173955 and Imatinib (STI-571)," *Cancer Research* 62:4236-4243 (2002)	
	A46	OBRECHT, *et al.*, "Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries," *Linker Mol. & Cleav. Strat.* P. 85.	
	A47	OWEN, *et al.*, "Two Structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product," *Curr. Biol. Ltd.* 3:467-482 (1995)	
	A48	PEARLMAN and CHARIFSON, "Are Free Energy Calculations Useful in Practice? A Comparison with Rapid Scoring Functions for the p38 MAP Kinase Protein System," *J. Med. Chem.* 44:3417-3423 (2001)	
	A49	RIPKA, *et al.*, "Aspartic Protease Inhibitors Designed from Computer-Generated Templates Bind as Predicted," *Org. Lett.* 15:2309-2312 (2001)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A50	ROSENBERRY et al., Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. The Journal of Biological Chemistry, 247 (5): 1555-15565, 1972.	
	A51	SICA et al., Affinity chromatography and the purification of estrogen receptors. The Journal of Biological Chemistry, 248 (18): 6543-6558, 1973.	
	A52	WILLETT, P., "Chemical Similarity Searching," *J. Chem. Inf. Comput. Sci.* 38:983-996 (1998)	
	A53	WUTHRICH, NMR-This other method for protein and nucleic acid structure determination. Acta Cryst., D51: 249-270, 1995.	
	A54	YANG ET AL., Peptide analogs from E-cadherin with different calcium-binding affinities. Journal of Peptide Research, 55:203-215, 2000.	
	A55	KEISS et al., Beta-Galactosidase decreases the binding affinity of the insulin-like-growth-factor-ii/mannose-6-phosphate receptor for the insulin-like-growth-factor II. European Journal of Biochemistry, 190:71-77, 1990	
	A56	BOS et al., The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9:165-169, 2000.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A57	BOGER et al., Synthesis of a functionalized rigid bicycle[2,2,1]heptane: a useful hapten for eliciting catalytic antibodies. Journal of Organic Chemistry, 59:5078-5079, 1994.	
	A58	PHAN et al., Extensively methylated myosin subfragment-1; Examination of local structure, interactions with nucleotides and actin, and ligand-induced conformational changes. Biochemistry, 33:11286-11295, 1994.	
	A59	MARYANOFF et al., Structure activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. Journal of Medicinal Chemistry, 41:1315-1343, 1998.	
	A60	MOCHIZUKI *et al.*, "Physical and Functional Interactions Between Pim-1 Kinase and Cdc25A Phosphatase," *The Journal of Biological Chemistry* 274:8659-18666, 1999	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.